Shots:
- Tetra and Targeted Pharmaceuticals collaborated with George Mason University NCBID to examine the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications
- The collaboration with Targeted provides expertise into the areas of drug development to expand the potential Return on Investment of ARDS-003
- The agreement will advance the antiviral CNS program, which is expected to grow to $163.05B in 2025
Click here to read full press release/ article | Ref: Tetra | Image: Yahoo Finance
The post Tetra Bio-Pharma Initiates Additional Studies of ARDS-003 in Neuroinflammation and Antiviral Diseases first appeared on PharmaShots.
